Tilray Retires $12M of Convertible Debt for 2.84M Shares in Fourth Swap
TLRY is trading near its 52-week low of $3.67 (14% above the low).
Summary
Tilray Brands exchanged $12 million of convertible notes for 2.84 million shares in its fourth debt-for-equity swap since June, continuing a pattern of debt reduction through shareholder dilution.
Key Events · Financing and Capital Events · TLRY
-
Fourth Debt-for-Equity Exchange
Between August 31 and September 8, 2026, Tilray issued 2,841,650 shares to retire $12 million principal of 5.20% Convertible Senior Notes due June 15, 2027.
-
Cumulative Dilution from Exchanges
Across four exchanges since June 30, Tilray has issued approximately 6.8 million shares to retire roughly $30 million of convertible debt, steadily expanding the share count.
-
Exchange Economics
At the current share price of $4.17, the 2.84M shares are worth approximately $11.8M, representing a modest discount to the $12M debt retired — noteholders accepting equity rather than holding to maturity.
-
Balance Sheet Improvement
The exchange reduces Tilray's outstanding convertible debt, lowering future interest obligations and potential maturity pressure, but at the cost of incremental shareholder dilution.
Analysis · TLRY · Life Sciences
Between August 31 and September 8, 2026, Tilray Brands issued 2,841,650 shares to noteholders to retire another $12 million of its 5.20% Convertible Senior Notes due 2027. This marks the fourth such exchange in roughly three months, following $12M for 2.64M shares on June 30 and $6M for 1.38M shares on August 10. The pattern indicates management is systematically reducing debt through equity issuance, which strengthens the balance sheet but steadily dilutes existing shareholders. At the current share price of $4.17, the 2.84M shares represent approximately $11.8M in equity value exchanged for $12M of debt — a modest discount for noteholders, suggesting they are willing to accept equity rather than hold to maturity. The cumulative effect of these exchanges is meaningful: roughly 6.8M shares issued across the four transactions, reducing debt by approximately $30M while expanding the share count.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.8% of the 1640 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLRY was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $563.9M. The 52-week trading range was $3.67 to $23.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.